12:47 PM EST - Helix BioPharma Corp : Is pleased to provide a corporate update on initiatives that were undertaken by the Company in 2021. During the second half of 2021, the Company initiated efforts to validate Helix; an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, and its lead clinical program with external stakeholders to bring in an outside perspective to the company's strategy and future. Helix BioPharma Corp
shares T.HBP are trading unchanged at $0.30.
